Evidence brief · Why Complete Elixir uses NMN

Topical NMN evidence brief

The same molecule, two different products. What the published research supports, what a formula has to solve, how we answer it, what our finished formulas did in practice, and the limits of all of it.

By Clara Song, Ph.D. · 12 references, each with a DOI link · Last reviewed 18 November 2026

English · Français · 한국어 · PDF version

Quick answer

Published research shows that nicotinamide mononucleotide (NMN) can raise NAD⁺ in human skin cells and influence pathways tied to mitochondrial function, cellular senescence and skin repair. NMN is also highly hydrophilic, formulation-sensitive and difficult to deliver through skin. The value of topical NMN therefore does not come from adding the ingredient. It comes from how the finished formula is designed, stabilised and delivered.

The point most NMN marketing skips

Two products naming the same molecule can differ completely. An INCI listing records that NMN was added at manufacture. It does not record how much intact NMN survives to the point of use, or whether any of it reaches living skin. Both are formulation outcomes rather than ingredient properties, and no label distinguishes them.

Prepared by
Clara Song, Ph.D., Founder & Formulator, Complete Elixir Skincare Inc.
Literature source
PubMed. A DOI link is given for every reference.
Scope
Topical application only. Oral NMN supplementation is a separate question and is not argued here.
How to read this
Section 01 sets out what the research supports. Section 02 sets out what a formula has to solve. Section 03 is how we answer it. Section 04 documents what our finished formulations did in practice, and Section 05 states the limits of all of it.
Published evidence peer-reviewed literature, with reference numbers
Formulation rationale why we build it this way
In-house observation what we saw in our own lab or practice
Section 01

What does the research support?

Two things are well established and predate any commercial interest in NMN: skin NAD⁺ declines with age and UV exposure, and supporting it topically is an established approach. On NMN itself, the published skin findings come from cells, skin models and animals.

Published evidence [1, 2]

Skin NAD⁺ declines with age and with UV exposure

Oblong's review in DNA Repair describes NAD⁺ and ATP depletion in skin as both an acute response to solar radiation and, cumulatively, a more permanent chronic reduction tied to mitochondrial damage, with cellular NAD⁺ pools known to be lower in aged skin.1 Fania and colleagues reach the same conclusion from the genomic-stability side: NAD⁺ depletion is associated with human skin aging, and NAD⁺ deficiency impairs the DNA damage response and increases genomic instability.2

Published evidence [2, 3]

Supporting skin NAD⁺ topically is an established approach, not a novel claim

Nicotinamide, the amide form of vitamin B3 and an NAD⁺ precursor, has decades of dermatological use, and clinical studies show topical nicotinamide reduces cutaneous aging changes.2,3

What has been published specifically on NMN in skin

Published evidence [4 to 9]

Finding What was shown Model
NMN behaves differently in skin from other NAD⁺ precursors Transcriptome analysis in human skin fibroblasts showed distinct gene-expression patterns for NMN versus nicotinamide riboside and nicotinamide. NMN raised cellular NAD⁺, activated sirtuin and autophagy pathways, enhanced mitochondrial function, suppressed cellular senescence and accelerated wound healing under oxidative stress and photo-aging conditions.4 In vitro, human skin fibroblasts
NMN can reach the skin compartment where it would matter NMN permeated a Strat-M artificial skin membrane and was detected by MALDI imaging mass spectrometry specifically in the papillary dermis region. Type I collagen production increased in human fibroblasts treated with NMN.5 Skin-permeation model plus cell culture
Topical delivery can raise NAD⁺ in a human epidermis model A fraction containing NMN, nicotinamide riboside and nicotinamide restored NAD⁺ in normal human epidermal keratinocytes even with NAMPT pharmacologically inhibited, and application to the stratum corneum of reconstructed human epidermis significantly reversed induced NAD⁺ depletion.6 Reconstructed human epidermis
Topical NAD⁺ protects fibroblasts against UV-induced and intrinsic aging Exogenous NAD⁺ showed protective effects against both UV-induced extrinsic aging and intrinsic aging in human fibroblasts, mediated by sirtuin activation, autophagy and mitochondrial function, and substantially boosted when CD38, which consumes NAD⁺, was inhibited.7 In vitro, human fibroblasts
NMN applied to skin accelerates repair in animal models An NMN-loaded hydrogel accelerated wound healing in diabetic mice through collagen synthesis, angiogenesis and antioxidant activity.8 NMN-loaded extracellular vesicles improved skin aging in mice through NAD/SIRT3-mediated mitophagy.9 Animal
Evidence map: where each published finding was studied A grid of six published findings against five kinds of model: human cells, artificial skin model, reconstructed epidermis, animal, and human topical trial. Reference 4 was studied in human cells. Reference 5 was studied in human cells and an artificial skin model. Reference 6 was studied in human cells and reconstructed epidermis. Reference 7 was studied in human cells. References 8 and 9 were studied in animals. The human topical trial column is marked not established for every finding. All other cells are not assessed in the cited study. Published finding [reference] Humancells Artificialskin model Reconstructedepidermis Animal Humantopical trial NMN raised NAD⁺, with a profile distinct from NR and nicotinamide, in human fibroblasts [4] NMN signal in the papillary dermis region of an artificial membrane; more Type I collagen in fibroblasts [5] A mixed precursor fraction (NMN, NR, nicotinamide) restored NAD⁺ in keratinocytes and reconstructed epidermis [6] Exogenous NAD⁺ protected fibroblasts against UV-induced and intrinsic ageing [7] NMN-loaded hydrogel: accelerated wound healing in diabetic mice [8] NMN-loaded vesicles: improved skin ageing in mice [9] Studied in this model Not established Not assessed in the cited study Evidence map: where each published finding was studied Six published findings, each followed by five marks for human cells, artificial skin model, reconstructed epidermis, animal, and human topical trial. Reference 4: human cells. Reference 5: human cells and artificial skin model. Reference 6: human cells and reconstructed epidermis. Reference 7: human cells. References 8 and 9: animal. The human topical trial column is marked not established for every finding. All other cells are not assessed in the cited study. Humancells Artificialskin model Reconstr.epidermis Animal Humantrial NMN raised NAD⁺, with a profile distinct from NR and nicotinamide, in human fibroblasts [4] NMN signal in the papillary dermis region of an artificial membrane; more Type I collagen in fibroblasts [5] A mixed precursor fraction restored NAD⁺ in keratinocytes and reconstructed epidermis [6] Exogenous NAD⁺ protected fibroblasts against UV-induced and intrinsic ageing [7] NMN-loaded hydrogel: accelerated wound healing in diabetic mice [8] NMN-loaded vesicles: improved skin ageing in mice [9] Studied in this model Not established Not assessed in the cited study
Published findingWhere each finding in section 01 was studied. The rows are the brief's findings only, with their reference numbers. The last column is the one to read: no finding here comes from a human topical trial, so that column is not established throughout. Not evidence that a product works.

Why reference 4 is the one that matters commercially

Most NAD⁺ skincare argument rests on nicotinamide, and the usual objection to NMN is that it is simply a more expensive way of delivering the same vitamin B3 activity. The fibroblast transcriptome work answers that directly: NMN produced a distinct gene-expression pattern from both nicotinamide riboside and nicotinamide, with significant differences between them, alongside NAD⁺ elevation, sirtuin and autophagy activation, senescence suppression and accelerated wound healing.4 The molecules are not interchangeable at the level of what skin cells actually do with them.

That is the case for the ingredient. The next section is the case for why the ingredient alone is not enough, and it is the part that separates one NMN product from another.

Section 02

What does a formula have to solve?

Hydrophilicity, poor permeability and instability, all at once. Three independent research groups, working on unrelated delivery problems, describe NMN's topical liability in almost the same words. Three practical consequences follow.

Published evidence [9, 10, 11]

Group one10

Topical application is hindered by high hydrophilicity, poor skin permeability and limited stability.

Group two9

High water solubility, low permeability and instability limit its clinical application.

Group three11

A promising compound, limited by instability and poor delivery control.

The three statements are paraphrased closely from the cited papers; the original sentences are in references 9, 10 and 11.

01

The label is a statement about the batching room, not about the skin

Formulation rationale

An INCI listing records that nicotinamide mononucleotide was added at manufacture. It does not record how much intact NMN remains at the moment of use, and it cannot record whether any of it crosses the stratum corneum. Both are formulation outcomes, not ingredient properties.

02

Stability belongs to the matrix, not to the molecule

Published evidence [5]

The one published shelf-life figure illustrates this well. NMN degradation followed first-order kinetics with a half-life of approximately seven months at 20 °C, but that figure is specific to the yeast-fermented filtrate the NMN was carried in.5 Change the water activity, the pH, the storage temperature, the light and air exposure, or the packaging, and the number changes with it. A product sitting on a shelf for a year in the wrong matrix may carry an accurate INCI list and very little active.

03

The delivery-systems literature exists because free NMN does not penetrate well

Published evidence [9, 10, 11]

Researchers are not building elaborate carriers for fun. Elastic cationic liposomal nanogels improved penetration by 22.7% relative to free NMN;10 PVA-coated liposomes and transethosomes were built to give NMN stable, pH-responsive transdermal release;11 stromal-cell vesicles were loaded with NMN by electroporation expressly to improve their stability and efficacy.9 Each of those papers is, implicitly, evidence that NMN dropped into a simple aqueous base is the weak case.

From the label to the skin: four stages, only the first is recorded on a label Four stages in sequence. Stage 1, added at manufacture, is what an ingredient list records. Stages 2 to 4, remains available at application, crosses the stratum corneum, and reaches viable epidermis, are formulation outcomes that no label records. Each of these is a formulation target, not demonstrated delivery. No quantities are shown. What a label records What no label records: formulation outcomes 01 Added at manufacture In the batching room 02 Remains available at application In the bottle, at the point of use 03 Crosses the stratum corneum At the skin's outer barrier 04 Reaches viable epidermis In living skin Recorded on the label; not demonstrated delivery Formulation target, not demonstrated delivery Formulation target, not demonstrated delivery Formulation target, not demonstrated delivery No quantities are shown. This is a map of the questions a formula has to answer, not a measurement. From the label to the skin: four stages, only the first is recorded on a label Four stages from top to bottom. Stage 1, added at manufacture, is what an ingredient list records. Stages 2 to 4, remains available at application, crosses the stratum corneum, and reaches viable epidermis, are formulation outcomes that no label records. Each is a formulation target, not demonstrated delivery. No quantities are shown. What a label records 01 Added at manufacture In the batching room On the label; not demonstrated delivery What no label records: formulation outcomes 02 Remains available at application In the bottle, at the point of use Formulation target, not demonstrated delivery 03 Crosses the stratum corneum At the skin's outer barrier Formulation target, not demonstrated delivery 04 Reaches viable epidermis In living skin Formulation target, not demonstrated delivery No quantities are shown. A map of the questions a formula has to answer, not a measurement.
Mechanism conceptThe path from the batching room to living skin. An ingredient list records stage 1 only. Stages 2 to 4 are what a formula is designed towards; each is a formulation target, not demonstrated delivery, and no percentage is claimed for any of them. Not evidence that a product works.

Questions worth asking of any NMN skincare product

  • What is the NMN concentration, and is it disclosed as a percentage rather than a marketing claim?
  • Is the base anhydrous, low-water or fully aqueous, and at what pH?
  • Is the NMN encapsulated or otherwise protected, or free in the base?
  • Is there stability data on the finished formula, and at what temperature and duration?
  • Is the packaging airless and opaque, and is any permeation claim based on the finished product rather than borrowed from a paper on a different matrix?
Section 03

How does Complete Elixir approach NMN?

By treating it as six formulation decisions, not one ingredient. We formulate and manufacture in our own lab in South Surrey, British Columbia, with no contract manufacturing, so every variable below is a decision we make and can account for.

Section 02 argued that an NMN product is decided by its formulation rather than its ingredient list. This section answers the obvious next question.

The six headings below are the same list we would hand a buyer to interrogate any NMN product on the market, including ours. We would rather compete on these six answers than on a percentage printed on a carton.

The Complete Elixir formulation bench: glass beakers on magnetic stirrers beside filled amber serum bottles
The formulation bench, South SurreyEach formula is weighed, mixed, filled and lot numbered in-house.
  1. ConcentrationNMN at 1%, across all five Youth Saver serums.
  2. Formula environmentA base built per SKU, pH controlled to each base.
  3. Stability strategyEncapsulated in a lamellar structure, with antioxidant protection, chelation and pH control.
  4. Manufacturing processNMN enters at phase 5, with a 43 °C ceiling at that point.
  5. Packaging and storage30 mL dropper bottles; glass matched to each formula.
  6. Finished-formula evaluationThree months at 45 °C in-house, and repeated-opening observation on every batch.
Youth Saver SKU Base Primary packaging
GREEN serum, 30 mL bottle and cartonGREEN Aqueous Standard
OASIS serum, 30 mL bottle and cartonOASIS Aqueous Standard
SHIELD serum, 30 mL bottle and cartonSHIELD Oil-in-water, high oil fraction Light-protective
ECLIPSE serum, 30 mL bottle and cartonECLIPSE Oil-in-water Light-protective
TWILIGHT serum, 30 mL bottle and cartonTWILIGHT Oil-in-water Light-protective
In-house observationThe six decisions, and the base and primary packaging of each of the five Youth Saver serums, as specified and recorded in our own lab. These are our own records, not third-party verification. Not evidence that a product works.
01

Concentration

Formulation rationale

NMN at 1%, across all five Youth Saver serums. We could print a larger number, and we chose not to. Above 1% we could not hold the active stably in these bases, and an unstable higher load is worth less than a stable lower one. With a molecule that permeates poorly, the constraint is how much NMN stays intact and reaches living skin, not how much entered the batch.

02

Formula environment

Formulation rationale

NMN is highly water-soluble and degrades in solution, so water activity is the largest single lever a formulator has. We build the base around the active and the skin type rather than reusing one base across the line, and pH is controlled to the range each base requires.

03

Stability strategy

Published evidence [5]Formulation rationale

Published NMN degradation follows first-order kinetics, and the one reported half-life, roughly seven months at 20 °C, belongs to the carrier matrix rather than to the molecule.5 We handle it as a matrix problem and apply four measures together: the NMN is encapsulated and carried in a lamellar structure, with antioxidant protection, chelation and pH control. No single one of these is unusual. Applying all four to a 1% load is the position.

04

Manufacturing process

Formulation rationale

An unstable hydrophilic active meets its worst conditions during compounding, not on the shelf. NMN enters at phase 5, with a 43 °C ceiling at that point. It is added late and cool rather than carried through the hot phase of the batch, which is the difference between a formula that contains NMN on paper and one that still contains it in the bottle.

Heated phases held on separate plates in the Complete Elixir laboratory
Heated phases, held separatelyEach phase sits on its own plate, so temperature is controlled per batch. NMN is not in the hot phase.
The compounding line: NMN is added in phase 5 under a 43 °C process ceiling A schematic of a five-phase batch with temperature on the vertical axis and no scale. The batch temperature rises through a hot phase in the earlier phases, then falls. NMN is added in phase 5, the last phase, below a dashed line marking the 43 °C process ceiling. Only the phase 5 ceiling is a stated value; the shape of the curve before phase 5 is illustrative. The ceiling is a process limit, not a measurement of how much NMN is preserved. Temperature (no scale) 43 °C process ceiling applies at phase 5 hot phase of the batch NMN added in phase 5, late and cool Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Only the phase 5 ceiling is a stated value. The dashed curve before phase 5 is illustrative, not a recorded temperature. The compounding line: NMN is added in phase 5 under a 43 °C process ceiling A schematic of a five-phase batch with temperature on the vertical axis and no scale. The batch temperature rises through a hot phase in the earlier phases, then falls. NMN is added in phase 5, the last phase, below a dashed line marking the 43 °C process ceiling. Only the phase 5 ceiling is a stated value; the curve before phase 5 is illustrative. The ceiling is a process limit, not a measurement of how much NMN is preserved. Temperature (no scale) 43 °C process ceiling hot phase NMN added in phase 5, late and cool 1 2 3 4 5 Phase Only the phase 5 ceiling is a stated value. The dashed curve before phase 5 is illustrative, not a recorded temperature.
Illustrative schematicThe compounding line, phases 1 to 5. NMN is added in phase 5 under a 43 °C process ceiling, late and cool, instead of being carried through the hot phase of the batch. This is a process ceiling, not measured NMN preservation. Not evidence that a product works.
05

Packaging and storage

Formulation rationale

All five serums ship in dropper bottles, with light-protective glass for SHIELD, ECLIPSE and TWILIGHT and standard glass for the two aqueous serums, matched to whether the formula carries a photosensitive oil phase. A dropper is not an airless pump, and we would rather say so than let a reviewer find it: the pipette returns to the bottle after each use and headspace increases across the life of the product. That is precisely why we test for it, which is the next point.

It is also why the serums are 30 mL (1 oz). We recommend use within six months of opening, and in practice most clients finish a bottle in three to four. The pack is sized to be used up inside that window rather than sized for perceived value and then left open past it. A larger bottle of an NMN serum in a dropper looks like better value and is a worse product.

06

Finished-formula evaluation

In-house observation

The distinction that matters is between documentation of the raw material and evaluation of the finished product. A supplier certificate describes the powder that arrived, not the serum that leaves. We evaluate finished formulas two ways.

Accelerated stability. Three months at 45 °C, in-house. The formulas held, with no phase separation. This is physical stability: no phase separation after three months at 45 °C; NMN content not assayed.

Repeated-opening observation, on every batch. Because the line ships in droppers, we open and close production units repeatedly across the period and watch for change, and we do this on every new batch rather than once at launch. ECLIPSE, TWILIGHT, OASIS and GREEN show no observable change. SHIELD develops a deepening of colour at around three months under repeated opening. We attribute that to partial oxidation of the magnesium ascorbyl phosphate in that formula rather than to the NMN: colour change on oxidation is characteristic of ascorbyl derivatives, and SHIELD is the only serum in the line where it appears. We have not assayed NMN content at that timepoint, so this is an attribution grounded in the chemistry rather than a measurement, and we would rather describe it that way.

Alongside this we issue batch-specific certificates of analysis and a certificate of manufacture carrying full INCI with content percentages, with raw-material documentation by CAS number and supplier across the line. Our testing is in-house; we say so rather than implying an accredited third-party programme we do not currently hold.

What this adds up to

A 1% load we can hold stably, in a base built per SKU rather than reused, with the active encapsulated in a lamellar structure and protected four ways, added late at 43 °C, packaged according to what each formula is vulnerable to, and watched batch by batch under the conditions the packaging actually creates. None of those decisions is visible on an ingredient list, and a brand that has never observed a change in any product at any timepoint has usually not looked.

Section 04

What did the finished formulations do in practice?

Three clients were documented on a standardised clinical imaging system at matched position and lighting. These are observational outcomes of complete protocols rather than tests of any single ingredient, and each is reported with what it does not establish.

No client images are published on this site. Time is given relative to the start of each protocol, and identifying details are generalised.

Case 01 · three months

Mature, sun-exposed skin

A mature client with long daily outdoor exposure, so high-dose UV and wind exposure continued throughout. Diffuse sun spots, persistent redness and visible fine vessels, crepey texture, a dehydrated and reactive barrier. Five weeks of homecare with ultrasound infusion and no needling or acids, then two microneedling sessions with homecare maintained throughout.

In-house observation

What was documented

Reduced visible redness and improved surface hydration during the conditioning phase alone, before any needling. Pigmentation, redness and texture continued to improve across three months. No post-inflammatory hyperpigmentation was observed despite continued UV exposure.

Published evidence [4, 5, 7]

What the literature makes plausible

The conditioning-phase change is the notable one, because no device injury had been introduced yet. Fibroblast work reports NMN raising NAD⁺, activating sirtuin and autophagy pathways and suppressing senescence under photo-aging conditions,4 and exogenous NAD⁺ protecting fibroblasts specifically against UV-induced aging.7 Increased Type I collagen in NMN-treated fibroblasts5 is consistent with the texture change.

Limit

What this case is not

A demonstration that NMN caused the result. The routine is multi-ingredient, ultrasound infusion was applied, and two microneedling sessions fall inside the window. No control site, no instrumental measurement, n = 1.

Read case study 01 in full

Case 02 · two months

Acne-prone, barrier-compromised skin

A client with more than ten years of continuous topical acne treatment (benzoyl peroxide and adapalene), both discontinued at protocol start. At intake the imaging system did not register a hydration reading at all, while inflamed blemishes remained visible. Four weekly ultrasound infusions, then one month on homecare alone.

In-house observation

What was documented

Visible inflamed blemishes decreased across two months while surface hydration and visible sebum improved. The result held through a further month on homecare alone, with no in-clinic step operating.

Published evidence [3, 4]

What the literature makes plausible

This is the case where barrier recovery and inflammation move together. NMN suppressed senescence and accelerated wound healing in fibroblasts,4 and nicotinamide's anti-inflammatory action in acne and rosacea is separately well documented.3 The homecare-only month is the more useful observation commercially, because the finished retail products were carrying it.

Limit

What this case is not

Evidence of mechanism. Discontinuing a decade of benzoyl peroxide and adapalene is itself a large change, and skin recovering from chronic irritant exposure often improves on withdrawal alone. This case cannot separate that from the formulation.

Read case study 02 in full

Case 03 · six months

Post-inflammatory hyperpigmentation

A client whose work keeps her outdoors most of the day, with sustained daily UV exposure that continued unchanged throughout, high sebum output and heavy comedonal congestion. Eight visits at three- to four-week intervals. Congestion was addressed first; the regimen shifted toward pigmentation at visit 4.

In-house observation

What was documented

A confluent field of red-brown marks across cheek and jaw resolved into discrete, lighter, separated marks with clear skin between them, and the red component underlying them cleared, while the client continued working outdoors daily.

Published evidence [1, 2, 7]

What the literature makes plausible

The sequencing is the clinically interesting part rather than the pigment result: inflammation was settled before pigment was addressed, which is standard reasoning for post-inflammatory hyperpigmentation. NAD⁺-related protection against UV-induced damage1,2,7 is a reasonable frame for improvement continuing under ongoing exposure.

Limit

What this case is not

Attributable to NMN or to any single component. The regimen changed mid-course by design, several products were involved, and six months of consistent professional attention is itself an intervention.

Read case study 03 in full

Why these are presented as formula outcomes rather than ingredient proof

A client does not apply an ingredient. She applies a finished product, in a sequence, over months. What these files document is how complete Complete Elixir formulations performed on three difficult skins under real conditions, including two clients whose UV exposure could not be removed from the picture. That is a different claim from "NMN did this", and it is deliberately the claim we make. The ingredient science in Section 01 explains why the formulations are built the way they are; it is not offered as proof of these outcomes.

Section 05

What are the limits of the evidence?

The biology is promising but early. No published randomised controlled trial of topical NMN on human facial skin was located in this search, and most of the work is in vitro, artificial-membrane or animal. Everything above is worth reading against the following, which we would rather state ourselves than have a reviewer find.

What is supported

  • Skin NAD⁺ declines with age and UV exposure.1,2
  • Topical NAD⁺ precursors are an established dermatological approach, with nicotinamide the best-evidenced.2,3
  • In human skin cells, NMN raises NAD⁺ and acts differently from nicotinamide riboside and nicotinamide at the transcriptome level.4
  • NMN can cross a skin-model membrane into the papillary dermis region and increase Type I collagen in fibroblasts.5

What is not yet supported

  • No published randomised controlled trial of topical NMN on human facial skin was located in this search.
  • No evidence that NMN outperforms nicotinamide topically in humans.
  • No dose-response relationship has been established for topical NMN.
  • The NMN skin literature is small. A narrow PubMed query returns six primary hits, and most work is in vitro, artificial-membrane or animal.
Published findingThe state of the published literature on topical NMN as this brief found it: what is supported, with reference numbers, beside what is not yet supported. Not evidence that a product works.

Counter-evidence we include deliberately

Published evidence [12]

Not every NAD⁺ precursor works in every cell type. In cultured normal human epidermal keratinocytes, nicotinic acid raised intracellular NAD⁺ roughly 1.3-fold, while nicotinamide and its derivatives failed to elicit any NAD⁺ response at all.12 The authors' conclusion is the one worth carrying: optimal precursor selection is cell-type dependent, and precursor choice for topical formulation has received little attention. "NMN is an NAD⁺ precursor" is therefore not, on its own, an argument that NMN works on skin. It has to be shown for skin, which is what reference 4 begins to do.

Which is exactly why we argue formulation rather than ingredient

If the evidence for NMN were overwhelming and the molecule were easy to deliver, every brand's NMN serum would work and the ingredient list would be a sufficient guide. Neither is true. The biology is promising but early, and the molecule is hydrophilic, poorly permeating and unstable.9,10,11 In that situation the difference between products is not which molecule is named on the box. It is whether the finished formula was built to keep it intact and get it in.

References

References

Literature retrieved from PubMed. A DOI link is given for every reference.

  1. Oblong JE. The evolving role of the NAD+/nicotinamide metabolome in skin homeostasis, cellular bioenergetics, and aging. DNA Repair (Amst). 2014;23:59–63. https://doi.org/10.1016/j.dnarep.2014.04.005
  2. Fania L, Mazzanti C, Campione E, Candi E, Abeni D, Dellambra E. Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention. Int J Mol Sci. 2019;20(23):5946. https://doi.org/10.3390/ijms20235946
  3. Camillo L, Zavattaro E, Savoia P. Nicotinamide: A Multifaceted Molecule in Skin Health and Beyond. Medicina (Kaunas). 2025;61(2):254. https://doi.org/10.3390/medicina61020254
  4. Kang S, Park J, Cho E, Kim D, Ye S, Jeong ET, Jun SH, Kang NG. Distinctive Gene Expression Profiles and Biological Responses of Skin Fibroblasts to Nicotinamide Mononucleotide: Implications for Longevity Effects on Skin. Biomedicines. 2025;13(10):2395. https://doi.org/10.3390/biomedicines13102395
  5. Betsuno R, Yamane T, Tsuji H, Nakajima Y, Imai M, Bamba T, Uchiyama S. Permeation of Nicotinamide Mononucleotide (NMN) in an Artificial Membrane as a Cosmetic Skin Permeability Test Model. J Cosmet Dermatol. 2025;24(5):e70222. https://doi.org/10.1111/jocd.70222
  6. Katayoshi T, Yamaura N, Nakajo T, Kitajima N, Tsuji-Naito K. Porcine placental extract increase the cellular NAD levels in human epidermal keratinocytes. Sci Rep. 2022;12(1):19040. https://doi.org/10.1038/s41598-022-23446-9
  7. Kang S, Park J, Cheng Z, Ye S, Jun SH, Kang NG. Novel Approach to Skin Anti-Aging: Boosting Pharmacological Effects of Exogenous Nicotinamide Adenine Dinucleotide (NAD) by Synergistic Inhibition of CD38 Expression. Cells. 2024;13(21):1799. https://doi.org/10.3390/cells13211799
  8. Liang Y, Li M, Tang Y, et al. Temperature-sensitive hydrogel dressing loaded with nicotinamide mononucleotide accelerating wound healing in diabetic mice. Biomed Pharmacother. 2023;167:115431. https://doi.org/10.1016/j.biopha.2023.115431
  9. Sun Z, Li J, Zheng Y, et al. Small extracellular vesicles derived from mesenchymal stromal cells loaded with β-nicotinamide mononucleotide activate NAD/SIRT3 signaling pathway-mediated mitochondrial autophagy to delay skin aging. Stem Cell Res Ther. 2025;16(1):339. https://doi.org/10.1186/s13287-025-04460-w
  10. Ye H, Zhen Y, Chen S, et al. Elastic cationic liposomal nanogels: a novel platform for topical nicotinamide mononucleotide delivery. J Liposome Res. 2025;36(1):13–24. https://doi.org/10.1080/08982104.2025.2584982
  11. Sabbagh F. pH-Responsive Transdermal Release from Poly(vinyl alcohol)-Coated Liposomes and Transethosomes: Investigating the Role of Coating in Delayed Drug Delivery. ACS Appl Bio Mater. 2025;8(5):4093–4103. https://doi.org/10.1021/acsabm.5c00257
  12. Oyama T, Yamamoto T, Kameda T, Kamiya T, Abe H, Abe T, Tanuma SI. Supplementation of Nicotinic Acid and Its Derivatives Up-Regulates Cellular NAD Level Rather than Nicotinamide Derivatives in Cultured Normal Human Epidermal Keratinocytes. Life (Basel). 2024;14(3):413. https://doi.org/10.3390/life14030413
Clara Song, Ph.D., founder and formulator of Complete Elixir, in a lab coat

Written and reviewed by Clara Song, Ph.D.

Founder and in-house formulator, COMPLETE ELIXIR · Ph.D. in Data Science · Medical Aesthetician Diploma

Last reviewed: 18 November 2026

This brief is prepared for scientific and commercial discussion. It makes no medical claim and describes no product as a treatment for any condition. Case documentation describes individual observational outcomes from one practice; results are not attributable to any single product or ingredient and individual results vary. It is educational and does not replace medical diagnosis or treatment.

When skin gets complicated, formulation matters.